Aurinia Pharmaceuticals (AUPH) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Aurinia Pharmaceuticals has reported a significant increase in its financials for Q2 2024, with a 38% growth in total net revenue and a 34% rise in net product revenue, alongside a strong cash position of $330.7 million. The company has also narrowed its revenue guidance for 2024 and is advancing its pipeline with the development of AUR200, a promising treatment for autoimmune diseases.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.